| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9914802 | TOLMAR | Sustained release polymer |
Nov, 2020
(3 years ago) | |
| US9539333 | TOLMAR | Sustained release polymer |
Nov, 2020
(3 years ago) | |
| US8470359 | TOLMAR | Sustained release polymer |
Oct, 2023
(6 months ago) | |
| US11771841 | TOLMAR | Systems and methods for mixing syringe valve assemblies |
Dec, 2041
(17 years from now) | |
Fensolvi Kit is owned by Tolmar.
Fensolvi Kit contains Leuprolide Acetate.
Fensolvi Kit has a total of 4 drug patents out of which 3 drug patents have expired.
Expired drug patents of Fensolvi Kit are:
- US9914802
- US9539333
- US8470359
Fensolvi Kit was authorised for market use on 01 May, 2020.
Fensolvi Kit is available in powder;subcutaneous dosage forms.
Fensolvi Kit can be used as method of treating pediatric patients 2 years of age and older with central precocious puberty.
The generics of Fensolvi Kit are possible to be released after 22 December, 2041.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-829) | May 01, 2023 |
Drugs and Companies using LEUPROLIDE ACETATE ingredient
Market Authorisation Date: 01 May, 2020
Treatment: Method of treating pediatric patients 2 years of age and older with central precocious puberty
Dosage: POWDER;SUBCUTANEOUS
FENSOLVI KIT family patents
